新型药用包装材料
Search documents
海顺新材涨2.12%,成交额2492.90万元,主力资金净流出96.64万元
Xin Lang Cai Jing· 2025-11-27 05:33
11月27日,海顺新材盘中上涨2.12%,截至13:09,报16.35元/股,成交2492.90万元,换手率1.23%,总 市值31.64亿元。 资金流向方面,主力资金净流出96.64万元,大单买入271.82万元,占比10.90%,卖出368.46万元,占比 14.78%。 海顺新材所属申万行业为:轻工制造-包装印刷-综合包装。所属概念板块包括:铝塑膜、小盘、锂电 池、固态电池、抗原检测等。 截至9月30日,海顺新材股东户数1.35万,较上期减少12.81%;人均流通股9274股,较上期增加 14.69%。2025年1月-9月,海顺新材实现营业收入8.23亿元,同比减少0.42%;归母净利润4866.55万元, 同比减少38.96%。 分红方面,海顺新材A股上市后累计派现2.96亿元。近三年,累计派现1.39亿元。 机构持仓方面,截止2025年9月30日,海顺新材十大流通股东中,医疗器械ETF(159883)位居第十大 流通股东,持股71.78万股,为新进股东。 责任编辑:小浪快报 海顺新材今年以来股价涨24.92%,近5个交易日跌4.27%,近20日涨3.09%,近60日涨2.32%。 资料显示,上海海顺 ...
海顺新材的前世今生:2025年三季度营收8.23亿居行业榜首,净利润5441.63万排名第二
Xin Lang Cai Jing· 2025-10-30 11:15
Core Insights - Haishun New Materials is a leading enterprise in the high-barrier packaging materials sector directly in contact with pharmaceuticals, established in 2005 and listed on the Shenzhen Stock Exchange in 2016 [1] Group 1: Business Performance - In Q3 2025, Haishun New Materials achieved a revenue of 823 million yuan, ranking first among six companies in the industry, with the second-ranked Tianyuan Co. generating 767 million yuan [2] - The revenue from new pharmaceutical packaging materials was 495 million yuan, accounting for 89.58% of total revenue, while other business revenue was 57.5 million yuan, making up 10.42% [2] - The net profit for the same period was 54.42 million yuan, placing the company second in the industry, with the first being Jinghua Laser at 73.13 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, the asset-liability ratio for Haishun New Materials was 38.56%, higher than the previous year's 34.82% and above the industry average of 37.97% [3] - The gross profit margin was 22.93%, down from 29.69% year-on-year but still above the industry average of 14.09% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 12.81% to 13,500, while the average number of circulating A-shares held per account increased by 14.69% to 9,274.86 [5] - The top ten circulating shareholders included a new entrant, the Medical Device ETF (159883), holding 717,800 shares [5] Group 4: Executive Compensation - The chairman and general manager, Lin Wuhui, received a salary of 912,300 yuan in 2024, a slight increase from 912,000 yuan in 2023 [4]